Dozens of states sue to dam the sale of 23andMe knowledge : NPR

[ad_1] <img src="https://npr.brightspotcdn.com/dims3/default/strip/false/crop/3096x2304+0+0/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F22%2Fc0%2F962c65a14dfbb9bf230e19bbe2fd%2Fap25161094295673.jpg" data-template="https://npr.brightspotcdn.com/dims3/default/strip/false/crop/3096x2304+0+0/resize/{width}/quality/{quality}/format/{format}/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F22%2Fc0%2F962c65a14dfbb9bf230e19bbe2fd%2Fap25161094295673.jpg" class="img" alt="A 23andMe saliva collection kit is shown on March 25, 2025, in Oakland, Calif." fetchpriority="high"/> A 23andMe saliva assortment package is proven on March 25, 2025, in Oakland, Calif. Barbara Ortutay/AP cover caption

toggle caption

Barbara Ortutay/AP PORTLAND, Ore. — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in chapter courtroom searching for to dam the sale of non-public genetic knowledge by 23andMe with out buyer consent. The lawsuit comes as a biotechnology firm seeks the courtroom's approval to purchase the struggling agency.

Organic samples, DNA knowledge, health-related traits and medical data are too delicate to be offered with out every particular person's specific, knowledgeable consent, Oregon Legal professional Normal Dan Rayfield stated in a information launch in regards to the lawsuit. Prospects ought to have the appropriate to manage such deeply private data and it can't be offered like strange property, it stated.

23andMe clients use saliva-based DNA testing kits to find out about their ancestry and discover long-lost relations. Based in 2006, the corporate additionally performed well being analysis and drug growth. But it surely struggled to discover a worthwhile enterprise mannequin since going public in 2021. In March it laid off 40% of its employees and filed for Chapter 11 chapter safety within the Japanese District of Missouri, elevating considerations in regards to the security of buyer knowledge.

Regeneron Prescription drugs stated final month it aimed to purchase the corporate for $256 million. Regeneron stated it will adjust to 23andMe's privateness insurance policies and relevant legislation. It stated it will course of all buyer private knowledge in accordance with the consents, privateness insurance policies and statements, phrases of service, and notices presently in impact and have safety controls in place designed to guard such knowledge.

A court-appointed, impartial client privateness ombudsman was attributable to look at the proposed sale and the way it would possibly have an effect on client privateness and report back to the courtroom by Tuesday.